London, 3 May 2011 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ DUBAI: HIK) (“Hikma”), the fast growing multinational pharmaceutical group, announces that it has completed its $112 million acquisition of Baxter Healthcare Corporation’s US generic injectables business (“Multi-Source Injectables” or “MSI”), significantly enhancing the scale and scope of its global Injectables platform.
As required by the United States Federal Trade Commission, Hikma will divest two West-Ward products, Phenytoin and Promethazine. This will not have a material impact on Hikma’s Injectables revenues and will not affect the expected contribution from Baxter’s Multi-Source Injectables business.
“The acquisition of Baxter’s MSI business is transformational for Hikma,” said CEO Said Darwazah. “The acquisition doubles the size of our global Injectables business and doubles our sales in the US market, while further diversifying our global revenue base. I am delighted to welcome our new employees and customers to Hikma.”
Hikma Pharmaceuticals PLC
+44 (0)20 7399 2760
Susan Ringdal, Investor Relations Director
+44 (0)20 7831 3113
Ben Atwell/Julia Phillips/Jonathan Birt/Matthew Cole
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2010, Hikma achieved revenues of $731 million and profit attributable to shareholders of $99 million. For news and other information, please visit www.hikma.com.
Holborn Gate, 26 Southampton Buildings
London, WC2A 1PB
D +44 (0)20 7269 7125